A novel exonic GHR splicing mutation (c.784G > C) in a patient with classical growth hormone insensitivity syndrome

Horm Res Paediatr. 2013;79(1):32-8. doi: 10.1159/000341527. Epub 2012 Sep 20.

Abstract

Context: Undetectable circulating growth hormone-binding protein (GHBP) can be indicative of a GH receptor (GHR) defect and cause GH insensitivity (GHI) syndrome.

Case report: The proband, severely growth retarded from birth, had a height of 73 cm (-6 SDS) and weight of 10.5 kg (-2.5 SDS) at the age of 3.25 years; her consanguineous parents were normal statured. Basal serum GH measurement was high, >40 ng/ml, while serum insulin-like growth factor-I (IGF-I; 8.5 ng/ml; normal, 13-100), IGF-binding protein 3 (126 ng/ml; normal, 365-1,294), acid labile subunit (0.59 mg/l; normal, 5.6-16), and GHBP (120 pmol/l; normal, 431-1,892) concentrations were all markedly low. Recombinant IGF-I therapy improved height to -4.4 SDS after 2.5 years of treatment.

Results: GHR gene analysis revealed a homozygous c.784G>C transversion, the last nucleotide of exon 7; the parents were heterozygous for the mutation. Evaluation of GHR mRNA indicated c.784G>C was not a missense mutation but induced exon 7 excision, leading to a frame shift and predicted early protein termination.

Conclusion: A novel homozygous GHRc.784G>C mutation, identified in a GHI patient, induced functional loss of the native intron 7 donor splice site, demonstrating, for the first time, the importance of exonic nucleotides at exon-intron junctions for normal GHR splicing.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Exons / genetics*
  • Female
  • Homozygote
  • Humans
  • Infant
  • Insulin-Like Growth Factor I / metabolism
  • Insulin-Like Growth Factor I / therapeutic use
  • Introns / genetics
  • Laron Syndrome / blood
  • Laron Syndrome / drug therapy
  • Laron Syndrome / genetics*
  • Mutation / genetics*
  • Receptors, Somatotropin / genetics*
  • Recombinant Proteins / therapeutic use
  • Treatment Outcome

Substances

  • Receptors, Somatotropin
  • Recombinant Proteins
  • Insulin-Like Growth Factor I